Collagen is the most abundant protein in the human body, mainly found in human skin, cartilage, tendon, heart and other parts of the body, with the function of maintaining the structural stability of tissues and organs, but also an important raw material and stabilising component in various tissue structures. The structure of collagen is formed by 3 alpha peptide chains of left-handed helical structure entwined in parallel, right-handed helical form with hydrogen bonds binding to each other, thus it has a strong tensile strength. Where the amino acids of the right-handed complex helical structural segment have a repeating sequence of (Glycine (Gly)-X-Y)n, with X and Y usually being proline and hydroxyproline. One in every three amino acid residues must pass through the central region of the triple helix, where the space is so narrow that only Gly can enter, which is why every other amino acid residue in its amino acid composition is Gly. The specific, stable structure of collagen is the basis for its widespread use as a biomaterial.
There are numerous types of collagens, which can be classified as Type I, Type II, Type III collagen, etc., based on the order of discovery. On the basis of structural complexity, it can be divided into fibrillar and non-fibrillar collagen. Non-fibrillar collagen can be further divided into various subtypes. Among them, type IV collagen is an important component of tissues such as the basement membrane, and plays an important role in the assembly and stabilization of the basement membrane. Type IV collagen is associated with a number of inherited or acquired disorders affecting multiple organs and tissues throughout the body including the kidneys, cochlea, eye, and smooth muscle.
A total of six type IV collagen isoforms (α1-α6) have been identified, encoded by the COL4A1-A6 genes. Different subtypes of type IV collagen have different affinity and characteristic recognition sites for the C-terminal non-collagenous (NC1) domain, resulting in the formation of three highly specific triple-helical protomers, α1α1α2, α3α4α5, and α5α5α6, which are secreted extracellularly. Head-to-head connections occur between the NC1 domains of the secreted protomers, forming a lattice-like collagen network that assembles into the basement membrane.
Figure 1. The formation of collagen IV scaffolds
(Source: Ivanov SV, et al. 2021)
Alternative Names
Type IV collagen
Collagen IV
References
1. Ivanov SV, et al. Collagen IV Exploits a Cl- Step Gradient for Scaffold Assembly. Adv Exp Med Biol. 2021;21:129-141.
2. Shoulders MD, et al. Collagen structure and stability. Annu Rev Biochem. 2009;78:929-58.
Molecular genetics of familial hematuric diseases
NEPHROLOGY DIALYSIS TRANSPLANTATION
Authors: Deltas, Constantinos; Pierides, Alkis; Voskarides, Konstantinos
Abstract
The familial hematuric diseases are a genetically heterogeneous group of monogenic conditions, caused by mutations in one of several genes. The major genes involved are the following: (i) the collagen IV genes COL4A3/A4/A5 that are expressed in the glomerular basement membranes (GBM) and are responsible for the most frequent forms of microscopic hematuria, namely Alport syndrome (X-linked or autosomal recessive) and thin basement membrane nephropathy (TBMN). (ii) The FN1 gene, expressed in the glomerulus and responsible for a rare form of glomerulopathy with fibronectin deposits (GFND). (iii) CFHR5 gene, a recently recognized regulator of the complement alternative pathway and mutated in a recently revisited form of inherited C3 glomerulonephritis (C3GN), characterized by isolated C3 deposits in the absence of immune complexes. A hallmark feature of all conditions is the age-dependent penetrance and a broad phenotypic heterogeneity in the sense that subsets of patients progress to added proteinuria or proteinuria and chronic renal failure that may or may not lead to end-stage kidney disease (ESKD) anywhere between the second and seventh decade of life. In addition to other excellent laboratory tools that assist the clinician in reaching the correct diagnosis, the molecular analysis emerges as the gold standard in establishing the diagnosis in many cases of doubt due to equivocal findings that complicate the differential diagnosis. Recent work led to the description of candidate genetic modifiers which confer a variable risk for progressing to chronic renal failure when co-inherited on the background of a primary glomerulopathy. Finally, more families are still waiting to be studied and more genes to be mapped and cloned that are responsible for other forms of heritable hematuric diseases. The study of such genes and their protein products will likely shed more light on the structure and function of the glomerular filtration barrier and other important glomerular components.
Endothelial cell-specific collagen type IV-alpha(3) expression does not rescue Alport syndrome in Col4a3(-/-) mice
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
Authors: Funk, Steven D.; Bayer, Raymond H.; Miner, Jeffrey H.
Abstract
The glomerular basement membrane (GBM) is a critical component of the kidney's blood filtration barrier. Alport syndrome, a hereditary disease leading to kidney failure, is caused by the loss or dysfunction of the GBM's major collagen type IV (COLA) isoform alpha(3),alpha(4),alpha(5). The constituent COL4 alpha-chains assemble into heterotrimers in the endoplasmic reticulum before secretion into the extracellular space. If any one of the alpha(3)-,alpha(4)- or alpha(5)-chains is lost due to mutation of one of the genes, then the entire heterotrimer is lost. Patients with Alport syndrome typically have mutations in the X-linked COL4A5 gene or uncommonly have the autosomal recessive form of the disease due to COL4A3 or COL4A4 mutations. Treatment for Alport syndrome is currently limited to angiotensin-converting enzyme inhibition or angiotensin receptor blockers. Experimental approaches in Alport mice have demonstrated that induced expression of COL4A3. either widely or specifically in podocytes of Col4a3(-/-) mice, can abrogate disease progression even after establishment of the abnormal GBM. While targeting podocytes in vivo for gene therapy is a significant challenge, the more accessible glomerular endothelium could be amenable for mutant gene repair. In the present study, we expressed COL4A3 in Col4a3(-/-) Alport mice using an endothelial cell-specific inducible transgenic system, but collagen-alpha(3)alpha(4)alpha(5) (IV) was not detected in the GBM or elsewhere, and the Alport phenotype was not rescued. Our results suggest that endothelial cells do not express the Col4a3/a4/a5 genes and should not be viewed as a target for gene therapy.